TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02794805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ¹³C-Octanoate Breath Test
Description: Octanoate Breath Test to be performed on subjects with suspected HCC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ¹³C-Octanoate Breath Test
Description: Octanoate Breath Test to be performed on subjects with suspected HCC
Study: NCT04767412

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise training, inspiratory muscle training
Description: All participants received 30 min of aerobic exercise training thrice per week for a period of 12 weeks, whereas the group B received an additional 30 min of IMT before each aerobic exercise session.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise training, inspiratory muscle training
Description: All participants received 30 min of aerobic exercise training thrice per week for a period of 12 weeks, whereas the group B received an additional 30 min of IMT before each aerobic exercise session.
Study: NCT00393380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parathyroid Hormone (teriparatide)
Description: Day +1: PTH 40 mcg, Day +2: PTH 60 mcg, Day +3: PTH 80 mcg, Day +4 to Day +29 or until ANC\>2000/microL: PTH 100 mcg
Study: NCT00927186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: 20 microgram (mcg) subcutaneous (SC) injection per day for 12 months. Placebo intravenous (IV) infusions were given to maintain blind.~After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: 5 milligram (mg) intravenous (IV) infusion administered once during 1 year study. Placebo subcutaneous (SC) injections were given to maintain blind.~After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension.
Study: NCT01759641

Intervention type: DEVICE
Intervention: Hypotension-prone patients
Description: Hemox optical sensor equips the dialysis monitors used during this trial. It is able to measure continuously, on arterial blood line, oxygen saturation, hematocrit and blood volume reduction.
Study: NCT02053584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dario™ Blood Glucose Meter
Description: Each subject will undergo a finger prick and also provide a venous blood sample

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YSI2003
Description: Blood samples will be tested using YSI (gold standard) for comparison to evaluate accuracy.
Study: NCT00950924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simultaneous Vision Bifocal Soft Contact Lenses
Description: Simultaneous Vision Bifocal Soft Contact Lenses will be prescribed such that the distance vision as measured by manifest subjective refraction will be properly corrected by the near vision add power and undercorrected by the distance power.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Single Vision Soft Contact Lenses
Description: Single vision soft contact lenses will be prescribed to properly correct the distance vision as measured by manifest subjective refraction.
Study: NCT01116843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: PF-00299804 or Placebo given pre-operatively for 7 to 11 days depending on surgery schedule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-00299804
Description: PF-00299804 or Placebo given pre-operatively for 7 to 11 days depending on surgery schedule.
Study: NCT00949663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of 1% human albumin in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of 1% human albumin in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of 1% human albumin in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose-dependent Insulinotropic Polypeptide (GIP)
Description: Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose-dependent Insulinotropic Polypeptide (GIP)
Description: Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose-dependent Insulinotropic Polypeptide (GIP)
Description: Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenin-25
Description: Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenin-25
Description: Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenin-25
Description: Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose-dependent Insulinotropic Polypeptide plus Xenin-25
Description: Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose-dependent Insulinotropic Polypeptide plus Xenin-25
Description: Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose-dependent Insulinotropic Polypeptide plus Xenin-25
Description: Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
Study: NCT03786575

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Next Generation Sequencing (NGS) detection
Description: The NGS detection panel is designed by our team and covers genes that are clinically useful and have definite guiding significance for endocrine therapy
Study: NCT02852733

Intervention type: OTHER
Intervention: end-of-life emergencies' management

Intervention type: OTHER
Intervention: end-of-life emergencies' management
Study: NCT01354535

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Isolated Locked Compression Plate
Description: A lateral thigh incision will be used to expose the fracture site. Surgeons will attempt to minimize devascularization of the bone by meticulous dissection and indirect reduction techniques. An appropriate sized plate will be applied to the lateral aspect of the femur. Fracture reduction will be achieved with the use of intra-operative fluoroscopy and the plate will be secured with locking screws.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cable Plating and Strut Allograft with Cerclage Wiring
Description: The plate will be placed laterally with the allograft strut placed on the anterior cortex. Screw fixation will be used distal to the stem and cables and screws will be used proximal to the stem tip. Cerclage cables or wires will be used to secure the strut.
Study: NCT02848352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo nasal spray

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo nasal spray

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Film Sequence

Intervention type: OTHER
Group type: OTHER
Intervention: Film Sequence

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Film Sequence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Film Sequence
Study: NCT01556100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DTBZ AV-133
Description: A total 40 PD subjects will be included in this study. PD subjects between 20 and 80 years of age may be eligible for this study. Candidates are screened with a medical history and physical examination, and blood test.
Study: NCT05391074

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: postbiotics (IGENH35.3A)
Description: postbiotics to induce microbiota epigenetic factors
Study: NCT04499677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ Ritonavir
Description: Dosage and method of administration: Day 1: 400mg/100 mg twice daily; Day 2 to Day 7: 200mg/50mg four (4) times daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Favipiravir Placebo
Description: Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Favipiravir Placebo
Description: Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lopinavir/ Ritonavir Placebo
Description: Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lopinavir/ Ritonavir Placebo
Description: Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
Study: NCT00714935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Counseling Program (DCP)
Description: An individual decisional counseling program (DCP) to help them comprehend the information, adjust this information to their personal illness history and elicit their preferences for cardiac risk fctor modification behavior in light of this personalized information

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coronary Artery Disease Decision Aid
Description: Coronary Artery Disease Decision Aid (CAD-DA) presented as a booklet called: Making Choices: Life Changes to Lower Your Risk of Heart Disease and Stroke~The CAD-DA is developed by the Ottawa Health Research Institute and Division of Clinical Epidemiology at Montreal General Hospital, in CAD patients facing the decision of making lifestyle changes to lower their cardiac risk factors and provides patients with information about what they can you do to prevent the disease from progressing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coronary Artery Disease Decision Aid
Description: Coronary Artery Disease Decision Aid (CAD-DA) presented as a booklet called: Making Choices: Life Changes to Lower Your Risk of Heart Disease and Stroke~The CAD-DA is developed by the Ottawa Health Research Institute and Division of Clinical Epidemiology at Montreal General Hospital, in CAD patients facing the decision of making lifestyle changes to lower their cardiac risk factors and provides patients with information about what they can you do to prevent the disease from progressing.
Study: NCT01207479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitalaTM
Description: A 43 day study design has been selected in order to capture meaningful safety and performance data of the Vitala™ device when used with these moldable products.
Study: NCT01315990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI + Cetuximab
Description: 1. Cetuximab (Erbitux® )- Cetuximab is a recombinant IgG1 chimeric monoclonal antibody directed against human epidermal growth factor receptor (EGFR).~2. FOLFIRI regimen~Administration Schedule:~Cetuximab at a initial dose 400 mg/sqm (first week), then 250 mg/sqm on day 1 and 8 Background Chemotherapy (every two weeks)~* Irinotecan 180 mg/m² iv , 90 min on day 1~* Folic acid (racemic) 400 mg/m², 120 min on day 1~* 5-FU 400 mg/m² bolus on day 1~* 5-FU 2400 mg/m² iv over 46 h on day 1 to 2
Study: NCT02247362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX2012Q
Description: Recombinant influenza HA vaccine consisting of two Influenza A subtypes and two Influenza B lineages and delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX2012Q
Description: Recombinant influenza HA vaccine consisting of two Influenza A subtypes and two Influenza B lineages and delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX2012Q
Description: Recombinant influenza HA vaccine consisting of two Influenza A subtypes and two Influenza B lineages and delivered IM

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaccine Diluent
Study: NCT05764096

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03254225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
Study: NCT03463226

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test
Description: Oxygen consumption (VO2) and carbon dioxide output (VCO2) were measured by means of gas exchange on a breath-by-breath basis. The patients were initially monitored for 2 minutes at rest when seated on the ergometer, after that they were instructed to pedal at a pace of 60-70 rpm and the completion of the test occurred when, in spite of verbal encouragement, the patient reached maximal volitional fatigue.
Study: NCT00645710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02235727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBR 900

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02128100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: * Oxaliplatin 85 mg/m² for over 2 hours,~* Leucovorin 400n mg/m² for over 2 hours,~* Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion~* Fluorouracil 400 mg/m² as a fast infusion over 15 minutes~* Fluorouracil 2400 mg/m² as a slow infusion over 46 hours
Study: NCT05391074

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamins (AREDS formulation and recommended daily dose)
Description: vitamins (AREDS to prevent AMD progression
Study: NCT02246985

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: The bread and mayonnaise in this meal does not have vegetable powders incorporated into them. Hence this meal does not contain carotenoids.
Study: NCT03463226

Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle Sympathetic Nerve Activity
Description: Multiunit post-ganglionic muscle sympathetic nerve recordings were made using a tungsten microelectrode placed in the peroneal nerve near the fibular head. Nerve signals were amplified by a factor of 50,000 to 100,000 and band-pass filtered (700 to 2000 Hz). For recording and analysis, nerve activity was rectified and integrated (time constant 0.1 seconds) to obtain a mean voltage display of sympathetic nerve activity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle Sympathetic Nerve Activity
Description: Multiunit post-ganglionic muscle sympathetic nerve recordings were made using a tungsten microelectrode placed in the peroneal nerve near the fibular head. Nerve signals were amplified by a factor of 50,000 to 100,000 and band-pass filtered (700 to 2000 Hz). For recording and analysis, nerve activity was rectified and integrated (time constant 0.1 seconds) to obtain a mean voltage display of sympathetic nerve activity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual-energy X-ray absorptiometry
Description: Dual-energy X-ray absorptiometry (DXA) scan was used to measure total lean mass, body fat and bone mineral content.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual-energy X-ray absorptiometry
Description: Dual-energy X-ray absorptiometry (DXA) scan was used to measure total lean mass, body fat and bone mineral content.

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous occlusion plethysmography
Description: Venous occlusion plethysmography was used to assess non-invasively blood flow.

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous occlusion plethysmography
Description: Venous occlusion plethysmography was used to assess non-invasively blood flow.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: Blood samples were drawn in the morning after 12h overnight fasting.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: Blood samples were drawn in the morning after 12h overnight fasting.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamometers for Handgrip Strength
Description: Muscle strength was assessed by handgrip dynamometer using the mean value of three attempts.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamometers for Handgrip Strength
Description: Muscle strength was assessed by handgrip dynamometer using the mean value of three attempts.
Study: NCT02246985

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vegetable bread only
Description: A vegetable powder (carrot and tomato) containing bread portion will be served alone. The amount of vegetable powder in the bread portion will be standardised to contain a known amount of carotenoids.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plain bread with vegetable mayonnaise
Description: Plain bread will be served with a vegetable powder (carrot and tomato) containing mayonnaise. The amount of vegetable powder in the mayonnaise will be standardised to contain a known amount of carotenoids.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vegetable bread with plain mayonnaise
Description: A vegetable powder (Carrot and tomato) containing bread portion will be served with plain mayonnaise. The amount of vegetable powder in the bread portion will be standardised to contain a known amount of carotenoids
Study: NCT04429594

Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling
Description: blood sampling at J0, M6, M12, M24, M36, M48, M60
Study: NCT00582452

Intervention type: OTHER
Intervention: Telephone survey
Description: Telephone survey
Study: NCT00404183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-Release Hydrocodone/Acetaminophen
Description: 2 tablets BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets BID
Study: NCT05157477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-based VR exporsure program
Description: This project seeks to establish a 8-week CBT-based VR exposure program to tackle sensory problems in ASD according to the theory of exposure and desensitization (both social and non-social scenarios) as well as identifying dysfunctional thought and searching for alternative thinking. In brief, this program aims to build up the core competence of the ASD individuals in facing the sensory environment, including (1) Relaxation skills (2) Ranking the fearful sensory situations (3) Anxiety coping strategy (3) Graded exposure (4) Cognitive appraisal and restructuring: identifying the dysfunctional thought when facing the social situations and figuring out alternative thinking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-based VR exporsure program
Description: This project seeks to establish a 8-week CBT-based VR exposure program to tackle sensory problems in ASD according to the theory of exposure and desensitization (both social and non-social scenarios) as well as identifying dysfunctional thought and searching for alternative thinking. In brief, this program aims to build up the core competence of the ASD individuals in facing the sensory environment, including (1) Relaxation skills (2) Ranking the fearful sensory situations (3) Anxiety coping strategy (3) Graded exposure (4) Cognitive appraisal and restructuring: identifying the dysfunctional thought when facing the social situations and figuring out alternative thinking.
Study: NCT01030133

Intervention type: DEVICE
Group type: OTHER
Intervention: Operator Role Real TMS
Description: In two of the four visits, the participant will be assigned to the operator condition receiving Real TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The operator's performance will control the painfulness delivered to both participants. Each participant will play each role twice.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Operator Role Real TMS
Description: In two of the four visits, the participant will be assigned to the operator condition receiving Real TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The operator's performance will control the painfulness delivered to both participants. Each participant will play each role twice.
Study: NCT01283425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InsuPatch
Description: Heaters for single use and a permanent control unit.
Study: NCT04037956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tubeless NOSES
Description: The whole procedures undergo by total laparoscopic surgery with no specimen extraction incision in the abdominal wall. The specimen then will be removed through natural orifice such (anal).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional laparoscopic radical resection
Description: The traditional laparoscopic operation undergo and then a small incision(5-8cm) is made in the middle of the lower abdominal wall to remove the specimen.
Study: NCT01954173

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D conformal radiation therapy
Description: Undergo conformal radiation therapy
Study: NCT02128100

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: 5 treatments of stereotactic ablative radiotherapy (SABR) over the course of two weeks with a minimum of 36 hours in between each treatment.
Study: NCT00373061

Intervention type: DRUG
Intervention: Xolair®
Description: This being an observational study, the study protocol does not specify any dose regimen.
Study: NCT04615585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aloe vera after SRP
Description: Subgingival administration of Aloe vera gel was preceded by flushing the area with saline to wash away any debris. Aloe vera (1cc) gel was applied subgingivally using atraumatic needle. Patients were instructed not to rinse or drink any liquid for at least 30 minutes. The application was performed at baseline and after 1 and 2 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing (SRP)
Description: Removal of supragingival and sub-gingival calculus and debris was performed, followed by smoothing root surfaces and removing cementum or dentine that is impregnated with calculus and toxins.